# Australian Radiation Protection and Nuclear Safety Agency

Entity Resources and Planned Performance

**Australian Radiation Protection and Nuclear Safety Agency**

[Section 1: Entity Overview and Resources 214](#_Toc71464819)

[1.1 Strategic Direction Statement 214](#_Toc71464820)

[1.2 Entity Resource Statement 215](#_Toc71464821)

[1.3 Budget Measures 215](#_Toc71464822)

[Section 2: Outcomes and Planned Performance 217](#_Toc71464823)

[2.1 Budgeted Expenses and Performance 217](#_Toc71464824)

[Section 3: Budgeted Financial Statements 222](#_Toc71464825)

[3.1 Budgeted Financial Statements 222](#_Toc71464826)

[3.2 Budgeted Financial Statements Tables 223](#_Toc71464827)

## Section 1: Entity Overview and Resources

### 1.1 Strategic Direction Statement[[1]](#footnote-1)

The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) is a non-corporate Commonwealth entity established under the *Australian Radiation Protection and Nuclear Safety Act 1998*. ARPANSA’s primary functions are to:

* promote uniformity of radiation protection and nuclear safety policy and practices across jurisdictions of the Commonwealth and states and territories
* provide advice on radiation protection, nuclear safety and related issues
* undertake research in relation to radiation protection, nuclear safety and medical exposures to radiation
* provide services relating to radiation protection, nuclear safety and medical exposures to radiation
* regulate nuclear installations, radiation facilities, legacy sites, radiation apparatus and radioactive material owned and operated by Commonwealth entities.

ARPANSA regularly assesses its operating environment, challenges, goals and risks to identify key priorities for coming years. In 2022–23, ARPANSA will continue to focus on key activities that reflect its statutory responsibilities, and will form the basis for ARPANSA’s health advice and risk-informed approach to effective regulation of radiation and nuclear facilities and practices.

The role and functions of ARPANSA are set out in the *Australian Radiation Protection, and Nuclear Safety Act 1998.* ARPANSA is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013.*

### 1.2 Entity Resource Statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: ARPANSA Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23Estimate**$'000 |
| **DEPARTMENTAL** |  |   |
| Prior year appropriation available | 6,499 | 6,499 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation (b) | 13,859 | 15,465 |
| s74 retained revenue receipts (c) | - | - |
| Departmental Capital Budget (b) (d) | 2,033 | 2,052 |
| Other services (e) |  |   |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **15,892** | **17,517** |

Table 1.1: ARPANSA Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022 (continued)

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23Estimate**$'000 |
| **Special accounts (f)** |  |  |
| Opening balance | 1,208 | 1,208 |
| Appropriation receipts | 19,500 | 17,517 |
| Non-appropriation receipts  | 12,829 | 12,939 |
| **Total special account** | **33,537** | **31,664** |
| Less appropriations drawn from annual or special appropriations above and credited to special accounts (g) | (19,500) | (17,517) |
| **Total departmental resourcing** | **36,428** | **38,163** |
| **Total resourcing for ARPANSA** | **36,428** | **38,163** |
|  |  |  |
|  | **2021–22** | **2022–23** |
| **Average staffing level (number)** | 144 | 146 |

All figures are GST exclusive.

(a) *Appropriation Act (No. 1) 2022–23.*

(b) $3.608m will be received through the 2021–22 Annual Appropriation Bill No.3. The annual appropriations received from this bill will be recognised in a future Portfolio Budget Statements but only after the Bills have received Royal Assent.

(c) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(d) Departmental Capital Budgets (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(e) *Appropriation Act (No. 2) 2022–23*.

(f) For further information on special appropriations and special accounts, please refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1.1 within this chapter for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

(g) Appropriation receipts included above.

### 1.3 Budget Measures

This section is not applicable to ARPANSA.

## Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to government outcomes over the Budget and forward years.

Each outcome is described within this section, together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

ARPANSA’s most recent Corporate Plan and Annual Performance Statement are available at: www.arpansa.gov.au/about-us/corporate-publications

### 2.1 Budgeted Expenses and Performance

**Outcome 1**

Protection of people and the environment through radiation protection and nuclear safety research, policy, advice, codes, standards, services and regulation

#### Program Contributing to Outcome 1

**Program 1.1: Radiation Protection and Nuclear Safety**

#### Linked Programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health (Health)Program 1.8: Health Protection, Emergency Response and RegulationHealth has strategic regulatory policy and national leadership responsibility for radiation protection and nuclear safety, with particular regard to the regulatory framework. This includes best practice for health technologies related to radiation and nuclear safety. |

#### Budgeted Expenses for ARPANSA

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses and Resources for ARPANSA

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **Program 1.1: Radiation Protection and Nuclear Safety** |  |  |  |
| Departmental expenses |  |   |  |  |  |
| Ordinary annual services (a) | 14,967 | 15,465 | 14,059 | 14,163 | 14,255 |
| Special accounts | 12,829 | 12,939 | 13,096 | 13,200 | 13,290 |
| Expenses not requiring appropriation in the Budget year (b) | 2,863 | 2,863 | 2,863 | 2,863 | 2,863 |
| Operating deficit (surplus) | - | - | - | - | - |
| **Total for Program 1.1** | **30,659** | **31,267** | **30,018** | **30,226** | **30,408** |
| **Total expenses for Outcome 1** | **30,659** | **31,267** | **30,018** | **30,226** | **30,408** |
|   |   |   |  |  |  |
|  | **2021–22** | **2022–23** |  |  |  |
| **Average staffing level (number)** | 144 | 146 |  |  |  |

(a) *Appropriation Act (No. 1) 2022–23.*

(b) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

#### Planned Performance for ARPANSA

Table 2.1.2 details the performance measures for the program associated with Outcome 1. It also provides the related key activities as expressed in the current Corporate Plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of 2022–23 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance Measures for ARPANSA

|  |
| --- |
| Outcome 1  |
| Protection of people and the environment through radiation protection and nuclear safety research, policy, advice, codes, standards, services and regulation. |
| Program Objective – Program 1.1: Radiation Protection and Nuclear Safety |
| Protect the Australian people and the environment from the harmful effects of radiation through effective, risk-informed regulation and delivery of services under the *Australian Radiation Protection and Nuclear Safety Act 1998*. Scientific knowledge and international best practice is applied to promote awareness of the effects of radiation and a nationally uniform approach to radiation protection of people (the public, workers and patients undergoing medical procedures using radiation) and the environment. |
| Key Activities |
| * Initiate, maintain, and promote frameworks for protection and safety.
* Undertake research and provide expert evaluations, advice, and services.
* Ensure effective and risk-informed regulation.
* Enhance organisational innovation and capability.
 |
| Performance Measures  |
| Provide high quality advice to the Australian Government and community on the health, safety and environmental risks from radiation. |
| Current Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results | Forward Estimates2023–26 Planned Performance Results |
| Evidence-based, risk-informed advice was provided to the Australian Government and community using expert, specialised resources and services to support protection of the public, workers and the environment from the hazards of both ionising and non‑ionising radiation.ARPANSA supported the Government’s Electromagnetic Energy (EME) Program to promote health and safety and address misinformation about EME emissions. A new research framework to facilitate research of EME exposures and health was launched.The Annual Summary Report of the Australian Radiation Incident Register (ARIR), covering incidents from 2020, was published on 22 December 2021. | Identify, assess and communicate the health, safety and environmental risks from radiation to the Australian Government and community through research, communication, provision of radiation protection services, and community consultation and awareness activities.Provide information, advice and standards on electromagnetic energy and health to the Australian Government and community through exposure assessment, research, facility upgrades and engagement with international health authorities.Provide support and analysis to the Nuclear-Powered Submarine Task Force to prepare a safety framework for nuclear-powered submarines. | As per 2022–23. |
| Provide emergency preparedness and response systems for a radiological or nuclear incident. |
| Current Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results | Forward Estimates2023–26 Planned Performance Results |
| Emergency preparedness and response systems for network and laboratory measurements, and information management and decision support systems, are operational and available to respond to an incident in alignment with the national planning framework. Field system maintenance and training was restored during 2021–22. Surveys to understand jurisdictional capacity and capability to respond were undertaken throughout the year. | Emergency preparedness and response systems for field, network and laboratory measurements, and information management and decision support systems, are calibrated, tested and exercised to ensure availability, and personnel are trained. | As per 2022–23. |

|  |
| --- |
| **Promote patient safety in radiotherapy and diagnostic radiology.** |
| **Current Year2021–22 Expected Performance Results** | **Budget Year2022–23 Planned Performance Results** | **Forward Estimates2023–26 Planned Performance Results** |
| The Australian Clinical Dosimetry Service (ACDS) report for 2020–21 was published on 22 November 2021.Annual publications are being developed on significant deviations and trends discovered through the Diagnostic Reference Level program for 2020. The report has a planned publication date of 31 March 2022.  | Report annually on significant deviations and trends discovered through the Australian Clinical Dosimetry Service and Diagnostic Level programs. | As per 2022–23. |
| **Ensure protection of people and the environment through efficient and effective regulation.** |
| Current Year2021–22 Expected Performance Results | Budget Year 2022–23 Planned Performance Results | Forward Estimates2023–26 Planned Performance Results |
| ARPANSA completed 11 of the findings addressed to it from the International Atomic Energy Agency Integrated Regulatory Review Service. Other findings progressed. Multi-jurisdictional findings falling under the Environmental Health Standing Committee (enHealth) were progressed. | Finalise the 14 ARPANSA‑specific findings from the International Atomic Energy Agency Integrated Regulatory Review Service mission to Australia. Support the implementation of multi-jurisdictional findings via the enHealth process, including development of the National Strategy for Radiation Protection. | As per 2022–23. |
| Material changes to Program 1.1 resulting from the following measures:There are no material changes to Program 1.1 resulting from measures. |

## Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2022–23 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted Financial Statements

#### 3.1.1 Differences between Entity Resourcing and Financial Statements

This section is not applicable to ARPANSA.

#### 3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

**Departmental Resources**

**Comprehensive Income Statement**

ARPANSA’s own sourced income is derived from the sale of scientific services such as the Personal Radiation Monitoring Service, the Comprehensive
Nuclear-Test-Ban Treaty Organisation contracts to operate and maintain monitoring stations, the Australian Clinical Dosimetry Service, and licence application fees and annual charges associated with ARPANSA’s regulatory activities.

In 2021–22 and 2022–23, ARPANSA received a transfer of funds from the Department of Defence to support the Nuclear-Powered Submarine Taskforce.

For the 2022–23 Budget and forward years, ARPANSA is anticipating a
break-even position net of unfunded depreciation and amortisation expenses.

**Balance Sheet**

ARPANSA’s total asset and liabilities are expected to remain stable over the forward years.

**Cash Flow**

Cash flows are consistent with projected income and expense, appropriations from Government and investments in property, plant and equipment.

### 3.2 Budgeted Financial Statements Tables

Table 3.1: Estimates of Special Account Flows and Balances

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | Outcome | Opening balance**2022–23***2021–22*$'000 | Other receipts**2022–23***2021–22*$'000 | Appropriation receipts**2022–23***2021–22*$'000 | Payments**2022–23***2021–22*$'000 | Closing balance **2022–23***2021–22*$'000 |
| **Departmental** |  |  |   |  |   |  |
| Special account by Act - ARPANSA Account (a) | 1 | **1,208** | **12,939** | **17,517** | **30,456** | *1,208* |
|  |   | *1,208* | *12,829* | *19,500* | *32,329* | *1,208* |
| **Total special accounts****2022-23 estimate** |  | **1,208** | **12,939** | **17,517** | **30,456** | **1,208** |
| *Total special accounts 2021–22 estimated actual* |   | *1,208* | *12,829* | *19,500* | *32,329* | *1,208* |

(a) *s56 Australian Radiation Protection and Nuclear Safety Act 1998.*

Table 3.2: Comprehensive Income Statement (showing net cost of services) for the period ended 30 June

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **EXPENSES** |  |   |  |  |  |
| Employee benefits | 19,453 | 19,832 | 18,950 | 19,151 | 19,246 |
| Supplier expenses | 8,090 | 8,313 | 7,946 | 7,953 | 8,052 |
| Depreciation and amortisation | 3,100 | 3,105 | 3,105 | 3,105 | 3,105 |
| Interest on RoU | 16 | 17 | 17 | 17 | 5 |
| **Total expenses** | **30,659** | **31,267** | **30,018** | **30,226** | **30,408** |
| **LESS:**  |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | 7,550 | 7,550 | 7,600 | 7,650 | 7,700 |
| Other revenue | 5,279 | 5,389 | 5,496 | 5,550 | 5,590 |
| **Total revenue** | **12,829** | **12,939** | **13,096** | **13,200** | **13,290** |
| **Gains** |  |  |  |  |  |
| Other | - | - | - | - | - |
| **Total gains** | **-** | **-** | **-** | **-** | **-** |
| **Total own-source income** | **12,829** | **12,939** | **13,096** | **13,200** | **13,290** |
| **Net cost of (contribution by) services** | **17,830** | **18,328** | **16,922** | **17,026** | **17,118** |
| Revenue from Government | 14,967 | 15,465 | 14,059 | 14,163 | 14,255 |
| **Surplus (deficit)** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** |
| **Surplus (deficit) attributable to the Australian Government** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income** | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** |
| **Note: Reconciliation of comprehensive income attributable to the agency** |
|  | **2021–22**$'000 | **2022–23**$'000 | **2023–24**$'000 | **2024–25** $'000 | **2025–26** $'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** | **(2,863)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 2,855 | 2,855 | 2,855 | 2,855 | 2,855 |
| plus depreciation and amortisation expenses for RoU | 245 | 250 | 250 | 250 | 250 |
| less lease principal repayments | (237) | (242) | (242) | (242) | (242) |
| **Total comprehensive income (loss) attributable to the agency** | **-** | **-** | **-** | **-** | **-** |

RoU = Right-of-Use asset

Table 3.3: Budgeted Departmental Balance Sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **ASSETS** |   |   |   |   |   |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 1,208 | 1,208 | 1,208 | 1,208 | 1,208 |
| Receivables | 6,192 | 6,192 | 6,192 | 6,192 | 6,192 |
| Accrued revenue | 531 | 531 | 531 | 531 | 531 |
| **Total financial assets** | **7,931** | **7,931** | **7,931** | **7,931** | **7,931** |
| **Non-financial assets** |  |   |  |  |  |
| Land and buildings | 28,275 | 27,470 | 27,665 | 26,610 | 25,682 |
| Property, plant and equipment | 11,821 | 11,773 | 11,740 | 11,723 | 11,679 |
| Inventories | 1,701 | 1,701 | 1,701 | 1,701 | 1,701 |
| Intangibles | 460 | 260 | 60 | 110 | 60 |
| Other | 564 | 564 | 564 | 564 | 564 |
| **Total non-financial assets** | **42,821** | **41,768** | **41,730** | **40,708** | **39,686** |
| **Total assets** | **50,752** | **49,699** | **49,661** | **48,639** | **47,617** |
| **LIABILITIES** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 429 | 429 | 429 | 429 | 429 |
| Employees | 390 | 390 | 390 | 390 | 390 |
| Other payables | 525 | 525 | 525 | 525 | 525 |
| **Total payables** | **1,344** | **1,344** | **1,344** | **1,344** | **1,344** |
| **Interest bearing liabilities** |  |  |  |  |  |
| Leases | 403 | 161 | 919 | 677 | 435 |
| **Total interest bearing liabilities** | **403** | **161** | **919** | **677** | **435** |
| **Provisions** |  |   |  |  |  |
| Employees | 5,735 | 5,735 | 5,735 | 5,735 | 5,735 |
| **Total provisions** | **5,735** | **5,735** | **5,735** | **5,735** | **5,735** |
| **Total liabilities** | **7,482** | **7,240** | **7,998** | **7,756** | **7,514** |
| **Net Assets** | **43,270** | **42,459** | **41,663** | **40,883** | **40,103** |
| **EQUITY** |  |   |  |  |  |
| Contributed equity | 41,010 | 43,062 | 45,129 | 47,212 | 49,295 |
| Reserves | 21,575 | 21,575 | 21,575 | 21,575 | 21,575 |
| Retained surpluses or (accumulated deficits) | (19,315) | (22,178) | (25,041) | (27,904) | (30,767) |
| **Total equity** | **43,270** | **42,459** | **41,663** | **40,883** | **40,103** |

Table 3.4: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings** $'000 | **Asset revaluation reserve** $'000 | **Contributed equity/capital** $'000 | **Total equity** $'000 |
| **Opening balance as at 1 July 2022** |  |  |  |  |
| Balance carried forward from previous period | (19,315) | 21,575 | 41,010 | **43,270** |
| Surplus (deficit) for the period | (2,863) | - | - | **(2,863)** |
| Capital budget - Bill 1 (DCB) | - | - | 2,052 | **2,052** |
| Equity injection - appropriation | - | - | - | **-** |
| **Estimated closing balance as at 30 June 2023** | **(22,178)** | **21,575** | **43,062** | **42,459** |

DCB = Departmental Capital Budget

Table 3.5: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Goods and services | 7,973 | 7,973 | 8,023 | 8,073 | 8,123 |
| Appropriations | 14,967 | 15,465 | 14,059 | 14,163 | 14,255 |
| Net GST received | 482 | 490 | 490 | 490 | 490 |
| Other | 5,279 | 5,389 | 5,496 | 5,550 | 5,590 |
| **Total cash received** | **28,701** | **29,317** | **28,068** | **28,276** | **28,458** |
| **Cash used** |  |   |  |  |  |
| Employees | 19,453 | 19,832 | 18,950 | 19,151 | 19,246 |
| Interest payments on lease liability | 16 | 17 | 17 | 17 | 5 |
| Suppliers | 8,572 | 8,803 | 8,436 | 8,443 | 8,542 |
| Other | - | - | - | - | - |
| Net GST paid | 423 | 423 | 423 | 423 | 423 |
| **Total cash used** | **28,464** | **29,075** | **27,826** | **28,034** | **28,216** |
| **Net cash from (or used by) operating activities** | **237** | **242** | **242** | **242** | **242** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash used** |  |   |  |  |  |
| Purchase of property, plant and equipment | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| **Total cash used** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |
| **Net cash from (or used by) investing activities** | **(4,533)** | **(2,052)** | **(2,067)** | **(2,083)** | **(2,083)** |
| **FINANCING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Capital budget - Bill 1 (DCB) | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| **Total cash received** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |
| **Cash used** |  |   |  |  |  |
| Lease principal repayments | 237 | 242 | 242 | 242 | 242 |
| **Total cash used** | **237** | **242** | **242** | **242** | **242** |
| **Net cash from (or used by) financing activities** | **4,296** | **1,810** | **1,825** | **1,841** | **1,841** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 1,208 | 1,208 | 1,208 | 1,208 | 1,208 |
| **Cash and cash equivalents at the end of the reporting period** | **1,208** | **1,208** | **1,208** | **1,208** | **1,208** |

DCB = Departmental Capital Budget

Table 3.6: Departmental Capital Budget Statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2021–22 Estimated actual** $'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate** $'000 | **2024–25 Forward estimate** $'000 | **2025–26 Forward estimate** $'000 |
| **CAPITAL APPROPRIATIONS** |   |   |   |   |   |
| Capital budget - Bill 1 (DCB) | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| Equity injections - Bill 2 | - | - | - | - | - |
| **Total capital appropriations** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |
| **Total new capital appropriations represented by:** |  |   |  |  |  |
| Purchase of non-financial assets | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| **Total items** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |  |   |  |  |  |
| Funded by capital appropriation - equity injection (a) | - | - | - | - | - |
| Funded by capital appropriation - DCB (b) | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| **Total acquisitions of non-financial assets** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |   |  |  |  |
| Total purchases | 4,533 | 2,052 | 2,067 | 2,083 | 2,083 |
| **Total cash used to acquire assets** | **4,533** | **2,052** | **2,067** | **2,083** | **2,083** |

DCB = Departmental Capital Budget

(a) Includes both current Bill 2 and prior Act 2, 4, 6 appropriations.

(b) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.7: Statement of Departmental Asset Movements (Budget year
2022–23)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Land** $'000 | **Buildings** $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |  |  |  |  |  |
| Gross book value  | 11,260 | 24,269 | 26,810 | 4,528 | **66,867** |
| Gross book value - RoU | - | 1,123 | - | - | **1,123** |
| Accumulated depreciation/amortisation and impairment | - | (7,649) | (14,989) | (4,068) | **(26,706)** |
| Accumulated depreciation/amortisation and impairment - RoU | - | (728) | - | - | **(728)** |
| **Opening net book balance** | **11,260** | **17,015** | **11,821** | **460** | **40,556** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |  |
| By purchase - appropriation ordinary annual services | - | 500 | 1,452 | 100 | **2,052** |
| By purchase - RoU | - | - | - | - | **-** |
| **Total additions** | **-** | **500** | **1,452** | **100** | **2,052** |
| **Other movements** |  |  |  |  |  |
| Depreciation/amortisation expense | - | (1,055) | (1,500) | (300) | **(2,855)** |
| Depreciation/amortisation expense - RoU | - | (250) | - | - | **(250)** |
| Other - RoU assets | - | - | - | - | **-** |
| **Total other movements** | **-** | **(1,305)** | **(1,500)** | **(300)** | **(3,105)** |
| **As at 30 June 2023** |  |  |  |  |  |
| Gross book value | 11,260 | 24,769 | 28,262 | 4,628 | **68,919** |
| Gross book value - RoU | - | 1,123 | - | - | **1,123** |
| Accumulated depreciation/amortisation and impairment | - | (8,704) | (16,489) | (4,368) | **(29,561)** |
| Accumulated depreciation/amortisation and impairment - RoU | - | (978) | - | - | **(978)** |
| **Closing net book balance** | **11,260** | **16,210** | **11,773** | **260** | **39,503** |

RoU = Right-of-Use Asset

1. For more information about the strategic direction of ARPANSA, refer to the current Corporate Plan, available at: [www.arpansa.gov.au/about-us/corporate-publications/corporate-plan](http://www.arpansa.gov.au/about-us/corporate-publications/corporate-plan) [↑](#footnote-ref-1)